Adma Biologics Inc. (ADMA)
NASDAQ · Healthcare
Adma Biologics Inc. EBITDA 2020–2025
Adma Biologics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Adma Biologics Inc. ebitda for the quarter ending March 31, 2026 was 53.1 M, a 41.96% increase year-over-year.
- Adma Biologics Inc. ebitda for the twelve months ending March 31, 2026 was 216.9 M.
- Adma Biologics Inc. annual ebitda for 2025 was 201.2 M, a 35.09% increase from 2024.
- Adma Biologics Inc. annual ebitda for 2024 was 148.9 M, a 375.91% increase from 2023.
- Adma Biologics Inc. annual ebitda for 2023 was 31.3 M, a 195.29% decrease from 2022.
- Adma Biologics Inc. annual ebitda for 2022 was -32.8 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Adma Biologics Inc. EBITDA — FAQ
Adma Biologics Inc. (ADMA) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ADMA's ebitda history?
The chart and table above show Adma Biologics Inc.'s ebitda by year and by quarter, including the growth rate.